Stifel raised the firm’s price target on Palvella Therapeutics (PVLA) to $60 from $45 and keeps a Buy rating on the shares. The firm, which has “high confidence” in the approaching Phase 3 SELVA readout of QTORIN rapamycin in microcystic lymphatic malformations, sees Palvella with “full capacity” to complete mLM development, advance in cutaneous venous malformations, and announce two new indications from the QTORIN platform
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PVLA:
- Palvella Completes Enrollment in Phase 3 SELVA Trial
- Palvella Therapeutics reports Q2 EPS (86c), consensus (77c)
- Snap downgraded, Leidos upgraded: Wall Street’s top analyst calls
- Palvella Therapeutics initiated with an Outperform at Raymond James
- Innovative QTORIN Platform and Promising Pipeline Drive Buy Rating for Palvella Therapeutics